Harbin Medisan Pharmaceutical Co., Ltd. (SZSE: 002900)
Health Care · Pharmaceuticals · CN
CN¥13.77
-1.08% today · -9.5% 1Y
Harbin Medisan Pharmaceutical Co., Ltd. (SZSE: 002900) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $648.01M and employs 2,086 people.
Over the last twelve months the share price has lost 9.5%, trading between 8.93 and 17.19.
Tweenvest scores Harbin Medisan Pharmaceutical Co., Ltd. across four factors: quality 55/100, value 51/100, growth 0/100. Its strongest factor is quality.
002900 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $648.01M
- Revenue (TTM)
- $117.90M
- P/E
- —
- EPS
- -0.98
- Dividend yield
- —
- Beta (5Y)
- 0.15
- 52-week high
- CN¥17.19
- 52-week low
- CN¥8.93
- Avg volume (3M)
- —
- Shares outstanding
- 316.35M
- Employees
- 2,086
- Next earnings
- —
About Harbin Medisan Pharmaceutical Co., Ltd.
Established in 1996 and based in Harbin, China, Harbin Medisan Pharmaceutical Co., Ltd. specializes in the full lifecycle of chemical pharmaceutical products within China, from research and development to manufacturing and sales. The company's comprehensive product line includes both active pharmaceutical ingredients (APIs) and various finished drug forms. Its offerings address a wide array of medical conditions, encompassing treatments for neurological, cardiovascular, and musculoskeletal systems, systemic infections, nutritional support, fluid balance, and other general healthcare needs.
- Founded
- 1996
- Listed since
- Sep 25, 2017
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,237.51 | -1.43% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $272.29 | +0.76% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.48 | -1.36% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.10 | -1.73% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.32 | -1.70% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.89 | -0.64% |
Figures last refreshed Aug 18, 2026.